DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA172465
Title:
Testing Experimental Compounds against Leishmaniasis in Laboratory Animal Model Systems.
Descriptive Note:
Annual summary rept. no. 1, 15 Dec 82-1 Sep 83,
Corporate Author:
CORNELL UNIV MEDICAL COLL NEW YORK DEPT OF MEDICINE
Report Date:
1983-09-01
Pagination or Media Count:
66.0
Abstract:
Pentostam and parasite dose responses have been determined for, and three WRAIR experimental compounds have been tested against visceral and mucocutaneous leishmaniasis. In addition, the conditions for screening compounds against mucocutaneous leishmaniasis caused by Leishmania braziliensis braziliensis M2904 WR464 in male BALBcByJ mice are presented. The major findings for screening against L. donovani Khartoum are 1. Amastigotes, stationary primary PCP or subcultured SP promastigo-tes from Schneiders drosophila medium cSDM yield equivalent liver burdens in mice. This allows 3 separate screening experiments from one hamster donor, increasing efficiency of testing. 2. The ED90 for Pentostam in this model is 10 mgkgday mkd x 5. This is 5 times less than previouslyu determined for Sudan strain L. donovani. 3. A single total dose of Pentostam is as effective as multiple doses. 4. Parasitic cure is obtained at 80 mkd x 5. 5. None of the three experimental compounds tested is competitive with Pentostam, although they are better tolerated than previously tested drugs. 6. Male mice are more sensitive to drug treatment than are females.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
